PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för gartisertib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

10 hits

Bibliografisk träff 2024-07-01

The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs.

Jo U, Arakawa Y, Zimmermann A, Taniyama D, Mizunuma M, Jenkins LM, Maity T, Kumar S, Zenke FT, Takebe N, Pommier Y.

Mol Cancer Ther · research-article; journal article · DOI 10.1158/1535-7163.mct-23-0402

Bibliografisk träff 2024-06-15

Chemo-Phosphoproteomic Profiling with ATR Inhibitors Berzosertib and Gartisertib Uncovers New Biomarkers and DNA Damage Response Regulators.

Jadav R, Weiland F, Noordermeer SM, Carroll T, Gao Y, Wang J, Zhou H, Lamoliatte F, Toth R, Macartney T, Brown F, Hastie CJ, Alabert C, van Attikum H, Zenke F, Masson JY, Rouse J.

Mol Cell Proteomics · research-article; journal article · DOI 10.1016/j.mcpro.2024.100802

Bibliografisk träff 2024-01-29

A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.

Burris HA, Berlin J, Arkenau T, Cote GM, Lolkema MP, Ferrer-Playan J, Kalapur A, Bolleddula J, Locatelli G, Goddemeier T, Gounaris I, de Bono J.

Br J Cancer · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1038/s41416-023-02436-2

Bibliografisk träff 2024-01-16

ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.

Lozinski M, Bowden NA, Graves MC, Fay M, Day BW, Stringer BW, Tooney PA.

Oncotarget · research support, non-u.s. gov't; research-article; journal article · DOI 10.18632/oncotarget.28551

Bibliografisk träff 2023-07-01

Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.

Turchick A, Zimmermann A, Chiu LY, Dahmen H, Elenbaas B, Zenke FT, Blaukat A, Vassilev LT.

Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/1535-7163.mct-22-0685

Bibliografisk träff 2022-12-22

ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma.

Seidel P, Rubarth A, Zodel K, Peighambari A, Neumann F, Federkiel Y, Huang H, Hoefflin R, Adlesic M, Witt C, Hoffmann DJ, Metzger P, Lindemann RK, Zenke FT, Schell C, Boerries M, von Elverfeldt D, Reichardt W, Follo M, Albers J, Frew IJ.

JCI Insight · research support, non-u.s. gov't; research-article; journal article · DOI 10.1172/jci.insight.156087

Bibliografisk träff 2021-05-27

Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.

Jo U, Senatorov IS, Zimmermann A, Saha LK, Murai Y, Kim SH, Rajapakse VN, Elloumi F, Takahashi N, Schultz CW, Thomas A, Zenke FT, Pommier Y.

Mol Cancer Ther · research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/1535-7163.mct-20-1026

Bibliografisk träff 2021-02-01

SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.

Jo U, Murai Y, Chakka S, Chen L, Cheng K, Murai J, Saha LK, Miller Jenkins LM, Pommier Y.

Proc Natl Acad Sci U S A · research support, n.i.h., intramural; research-article; journal article · DOI 10.1073/pnas.2015654118

Bibliografisk träff 2020-02-26

Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy.

Gorecki L, Andrs M, Rezacova M, Korabecny J.

Pharmacol Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.pharmthera.2020.107518

Bibliografisk träff 2019-12-11

Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?

Bradbury A, Hall S, Curtin N, Drew Y.

Pharmacol Ther · review; journal article · DOI 10.1016/j.pharmthera.2019.107450